Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC
September 13, 2026
September 13, 2026
AURORA, Colorado, Sept. 13 [Category: Medical] -- The International Association for the Study of Lung Cancer posted the following news release:
* * *
Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC
*
(SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) - First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improve . . .
* * *
Phase 3 DESTINY-Lung04 Trial Shows First-Line Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in HER2-Mutant NSCLC
*
(SEOUL, Republic of Korea -September 14th at 10:45 a.m. Korea Standard Time) - First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improve . . .